Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IMX-110

Other · Inhibitor of STAT3, NF-kB (NFKB1) and topoisomerase II (TOP2A) · developed by Immix Biopharma

Phase 1/2 Most advanced trial (none active)

IMMX Developer

1 Registered trials

What is IMX-110?

IMX-110 is a nanoparticle formulation encapsulating curcumin and doxorubicin. Curcumin inhibits STAT3 and NF-kB signaling, while doxorubicin intercalates DNA and inhibits topoisomerase II, inducing apoptosis. The formulation is studied in pancreatic, breast, and ovarian cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Targets: STAT3, NF-kB (NFKB1), topoisomerase II (TOP2A)
Mechanism: Inhibitor of STAT3, NF-kB (NFKB1) and topoisomerase II (TOP2A)
Pathways: STAT3 signaling, NF-kB signaling, DNA replication, apoptosis
Therapy area: Oncology
Developer: Immix Biopharma, Inc. (IMMX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03382340	Phase 1/2	Solid Tumor, Adult	Unknown	IMMX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsBreast CancerOvarian CancerPancreatic CancerSolid Tumor, Adult

Other drugs acting on STAT3 / NFKB1 / TOP2A

Doxorubicin FDA approved Amrubicin Phase 3 Berubicin Phase 2 Camsirubicin Phase 1 Pegylated Liposomal Doxorubicin Phase 3 WP1066 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IMMX page.

Follow IMMX, the company behind IMX-110

See IMMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMMX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z